AMANTA
Amanta Healthcare Limited (AMANTA) Stock Analysis
Amanta Healthcare Limited is an Indian pharmaceutical company manufacturing sterile injectables and formulations. It supplies hospital and regulated market products from manufacturing plants in India. The company focuses on injectable CDMO and own-brand opportunities. It is a recently listed pharma company.
Healthcare › Drug Manufacturers - Specialty & Generic
₹183.40
-2.14% 1W | +50.90% 52W
Market Cap
712 CR
P/E Ratio
44.1
52W High
₹209.9
52W Low
₹92
Div. Yield
0%
Beta
–
50 DMA
₹185.3
200 DMA
₹141.3
Profit Margin
5%
Inst. Own.
7.2%
📊 CONSOLIDATION
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 68.10 | 66.73 | 67.81 | 72.06 | 65.31 | 70.89 | 74.49 | 76.99 | 68.80 |
| Expenses | 54.70 | 52.85 | 52.75 | 53.10 | 50.41 | 56.24 | 59.13 | 62.03 | 54.26 |
| Operating Profit | 13.40 | 13.88 | 15.06 | 18.96 | 14.90 | 14.65 | 15.36 | 14.96 | 14.54 |
| OPM % | 19.68% | 20.80% | 22.21% | 26.31% | 22.81% | 20.67% | 20.62% | 19.43% | 21.13% |
| Other Income | 0.15 | 0.21 | 0.87 | 0.16 | 0.96 | -2.56 | 0.68 | 1.66 | 0.64 |
| Interest | 9.45 | 6.32 | 5.90 | 6.28 | 6.29 | 5.15 | 5.06 | 4.25 | 6.00 |
| Depreciation | 4.60 | 4.60 | 4.51 | 4.69 | 4.64 | 4.66 | 4.67 | 4.75 | 4.69 |
| Profit before tax | -0.50 | 3.17 | 5.52 | 8.15 | 4.93 | 2.28 | 6.31 | 7.62 | 4.49 |
| Tax % | -28.00% | 28.71% | 22.64% | 26.87% | 28.80% | 46.93% | 26.47% | 27.43% | 26.28% |
| Net Profit | -0.36 | 2.26 | 4.28 | 5.96 | 3.51 | 1.21 | 4.63 | 5.53 | 3.31 |
| EPS in Rs | -0.13 | 0.78 | 1.48 | 2.07 | 1.22 | 0.31 | 1.19 | 1.42 | 0.85 |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 171 | 225 | 259 | 280 | 275 | 288 | 291 |
| Expenses | 147 | 133 | 173 | 206 | 223 | 215 | 228 | 232 |
| Operating Profit | 37 | 38 | 52 | 53 | 58 | 60 | 60 | 60 |
| OPM % | 20% | 22% | 23% | 20% | 21% | 22% | 21% | 20% |
| Other Income | 2 | 1 | 76 | 4 | 1 | 1 | 1 | 0 |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 | 21 | 20 |
| Depreciation | 16 | 17 | 17 | 18 | 20 | 18 | 19 | 19 |
| Profit before tax | -15 | -18 | 62 | 3 | 5 | 15 | 21 | 21 |
| Tax % | 25% | 23% | 11% | 179% | 32% | 29% | 30% | |
| Net Profit | -19 | -22 | 55 | -2 | 4 | 10 | 15 | 15 |
| EPS in Rs | -7.03 | -8.14 | 20.54 | -0.79 | 1.35 | 3.64 | 3.83 | 3.77 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 4.0% | 11.0% | – |
| Profit CAGR | 114.0% | 22.0% | – |
Shareholding Pattern
Promoters63.56%
FIIs1.00%
DIIs11.34%
Public24.10%
Promoters63.56%
FIIs1.10%
DIIs11.24%
Public24.09%
Promoters63.72%
FIIs0.85%
DIIs12.88%
Public22.55%
Promoters63.79%
FIIs0.43%
DIIs12.92%
Public22.84%
Promoters63.72%
FIIs0.85%
DIIs12.88%
Public22.55%
Promoters63.79%
FIIs0.43%
DIIs12.92%
Public22.84%
AMANTA
Holdings Analysis
Key strengths & risk signals
58
Overall
45
Fundamental
71
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (183.4) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -2.1% (1 week), -3.4% (1 month), 9.2% (3 months).
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
BULLISH TREND! 50-day average (185.3) is above 200-day average (141.3) - positive signal.
EXCELLENT YEAR! Stock gained 50.9% in the last year.
BULLISH SENTIMENT! In last 30 days: 14 up days, 14 down days. Avg volume on up days: 48,949 vs down days: 40,696. Ratio: 1.2x
Fundamental & Technical Analysis
58Overall
45Fundamental
71Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 3.3% (SLOW, 5/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
3/10
LOW MARGIN! 5.0% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.1% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (185.3) is above 200-day average (141.3) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (183.4) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 50.9% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 14 down days. Avg volume on up days: 48,949 vs down days: 40,696. Ratio: 1.2x
RSI
3/5
NEUTRAL! RSI at 46.7 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 77.5% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -2.1% (1 week), -3.4% (1 month), 9.2% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
AMANTA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-08 | Concall PDF | |
| Q4FY262026-05-21 | Concall PDF | |
| Q3FY262026-02-16 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMANTA | ₹183.40 | 44.1 | 5.0% | 3.3% | – | +50.9% | 58 | BREAKDOWN | -5.7% | -40.0% | +5.4% | -10.6% |
| VALIANTLAB | ₹134.70 | 47.9 | 5.2% | -10.7% | – | +48.0% | 64 | BREAKDOWN | +1,072.2% | +1,072.2% | +146.4% | +25.3% |
| WANBURY | ₹192.40 | 11.8 | 8.6% | 8.9% | – | -16.9% | 52 | APPROACHING RESISTANCE | -76.3% | -85.3% | +1.5% | +0.6% |
| ZIMLAB | ₹144.80 | 176.5 | 0.9% | -2.5% | -37.9% | +112.5% | 58 | CONSOLIDATING UP | +110.5% | -208.1% | +31.2% | -10.5% |
| KILITCH | ₹230.40 | 26.2 | 12.7% | 19.2% | 42.4% | +23.4% | 84 | BREAKOUT | -3.3% | -80.0% | +4.2% | -49.9% |
| ANUHPHR | ₹82.60 | 18.7 | 5.7% | 13.5% | 4.3% | +5.1% | 65 | BREAKDOWN | +37.3% | -2.6% | +3.9% | -4.1% |
| ALBERTDAVD | ₹831.00 | 21 | 6.2% | -1.1% | – | +1.5% | 51 | APPROACHING SUPPORT | +305.1% | -249.5% | +43.5% | +17.9% |
| THEMISMED | ₹106.50 | 24.6 | 12.1% | -0.4% | -72.8% | -14.1% | 53 | BREAKDOWN | -273.2% | +176.4% | -10.9% | +13.7% |
Data from TradeAlone · Updated daily
AMANTA News
Amanta Healthcare Limited Q2 & H1fy27 Results: Revenue Up 17%, PAT Surges 26%2026-11-04Amanta Healthcare Limited (amanta) Announces Q1fy27 Results: Stable Margins, Strategic Capacity Build-out Continues2026-08-05Amanta Healthcare Limited (NSE: Amanta) Q4 & FY26: Consistent Revenue Momentum, 42% Yoy Profit Growth in FY262026-05-19
